N-[(E)-(4-bromo-3,5-dimethoxyphenyl)methylideneamino]-2-(4-morpholin-4-ylphenyl)-2-propan-2-yloxyacetamide | 1207549-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-[(E)-(4-bromo-3,5-dimethoxyphenyl)methylideneamino]-2-(4-morpholin-4-ylphenyl)-2-propan-2-yloxyacetamide
• CAS: 1207549-80-1
• 化学式: C₂₄H₃₀BrN₃O₅
• 分子量: 520.423
• InChiKey: NWJMEFXDCFJUJO-CVKSISIWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  81.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  在 溶剂黄146 、 肼 作用下， 以 乙醇 为溶剂， 生成 N-[(E)-(4-bromo-3,5-dimethoxyphenyl)methylideneamino]-2-(4-morpholin-4-ylphenyl)-2-propan-2-yloxyacetamide
  参考文献：
  名称：

  Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia

  摘要：

  A series of 2-methoxyacylhydrazones were optimized to yield compounds with high affinity for PDE10A. Several compounds demonstrated efficacy in animal models of schizophrenia, including conditioned avoidance response and a pro-psychotic phencyclidine hyperactivity model. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.007

文献信息

• PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
  申请人：Cutshall Neil S.

  公开号：US20100035872A1

  公开（公告）日：2010-02-11

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

  揭示了抑制PDE10的化合物，可用于治疗多种疾病，包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病，如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑性瘫痪、睡眠障碍、疼痛、抽动症、精神分裂症、妄想症、药物诱导的精神病和惊恐症以及强迫症。此外，还提供了这些化合物的药用盐、立体异构体、溶剂合物和前药。还揭示了含有化合物的组合物，与药用载体结合，以及与使用这些组合物抑制温血动物中的PDE10相关的方法。
• US8377930B2
  申请人：——

  公开号：US8377930B2

  公开（公告）日：2013-02-19
• US9783521B2
  申请人：——

  公开号：US9783521B2

  公开（公告）日：2017-10-10
• Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia
  作者：Neil S. Cutshall、Rene Onrust、Alex Rohde、Sasha Gragerov、Lauren Hamilton、Kevin Harbol、Hui-Rong Shen、Shawn McKee、Charles Zuta、Galina Gragerova、Vince Florio、Thomas N. Wheeler、Jennifer L. Gage

  DOI：10.1016/j.bmcl.2012.07.007

  日期：2012.9

  A series of 2-methoxyacylhydrazones were optimized to yield compounds with high affinity for PDE10A. Several compounds demonstrated efficacy in animal models of schizophrenia, including conditioned avoidance response and a pro-psychotic phencyclidine hyperactivity model. (C) 2012 Elsevier Ltd. All rights reserved.